middle.news
How Alterity’s AI-Powered MRI Biomarker Could Transform MSA Diagnosis and Care
10:31am on Thursday 24th of July, 2025 AEST
•
Biotechnology
Read Story
How Alterity’s AI-Powered MRI Biomarker Could Transform MSA Diagnosis and Care
10:31am on Thursday 24th of July, 2025 AEST
Key Points
Development of the MSA Atrophy Index (MSA-AI) using AI-driven MRI analysis
MSA-AI correlates strongly with clinical severity and disease progression
MSA-AI distinguishes Multiple System Atrophy from related disorders like Parkinson’s disease
Study supports use of MSA-AI in Alterity’s ongoing Phase 2 and planned Phase 3 clinical trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE